<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="vlcad" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">vlcad</book-part-id>
      <title-group>
        <title>Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonyms: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency, VLCAD Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Leslie</surname>
            <given-names>Nancy D</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Professor of Clinical Pediatrics, Division of Human Genetics<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>Nancy.Leslie@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Valencia</surname>
            <given-names>C Alexander</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Assistant Professor of Clinical Pediatrics, Division of Human Genetics<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>Alexander.Valencia@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Strauss</surname>
            <given-names>Arnold W</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Professor of Pediatrics, Heart Institute, Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>Arnold.Strauss@cchmc.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Connor</surname>
            <given-names>Jessica A</given-names>
          </name>
          <degrees>MS</degrees>
          <aff>Counsyl, Inc<break/>South San Francisco, California</aff>
          <email>jconnor@counsyl.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhang</surname>
            <given-names>Kejian</given-names>
          </name>
          <degrees>MD, MBA</degrees>
          <aff>Associate Professor of Clinical Pediatrics, Division of Human Genetics<break/>Cincinnati Children&#x02019;s Hospital Medical Center<break/>Cincinnati, Ohio</aff>
          <email>Kejian.Zhang@cchmc.org</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2009-05-28" date-type="created">
          <day>28</day>
          <month>5</month>
          <year>2009</year>
        </date>
        <date iso-8601-date="2014-09-11" date-type="updated">
          <day>11</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="eds4" document-type="chapter">Vascular Ehlers-Danlos Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="vhl" document-type="chapter">Von Hippel-Lindau Syndrome</related-object>
      <abstract id="vlcad.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Deficiency of very long-chain acyl-CoA dehydrogenase (VLCAD), which catalyzes the initial step of mitochondrial &#x003b2;-oxidation of long-chain fatty acids with a chain length of 14 to 20 carbons, is associated with three phenotypes. The severe early-onset cardiac and multi-organ failure form typically presents in the first months of life with hypertrophic or dilated cardiomyopathy, pericardial effusion, and arrhythmias, as well as hypotonia, hepatomegaly, and intermittent hypoglycemia. The hepatic or hypoketotic hypoglycemic form typically presents during early childhood with hypoketotic hypoglycemia and hepatomegaly, but without cardiomyopathy. The later-onset episodic myopathic form presents with intermittent rhabdomyolysis, muscle cramps and/or pain, and/or exercise intolerance. Hypoglycemia typically is not present at the time of symptoms.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis relies on (1) comprehensive acylcarnitine analysis by tandem mass spectrometry of plasma or a dried blood spot specimen collected during a period of metabolic stress (especially fasting or reduced caloric intake during infectious illness or procedures), followed by (2) molecular genetic testing of <italic toggle="yes">ACADVL,</italic> the only gene in which pathogenic variants are known to cause VLCAD deficiency (VLCADD). Additional diagnostic tests are functional analyses of fatty acid oxidation in cultured fibroblasts and measurement of VLCAD enzyme activity in fibroblasts or lymphocytes.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Use of intravenous (IV) glucose as an energy source, treatment of cardiac rhythm disturbance, and monitoring of rhabdomyolysis. Cardiac dysfunction is reversible with early, intensive supportive care (occasionally including extra-corporeal membrane oxygenation) and diet modification.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Individuals with the more severe forms are typically placed on a low-fat formula, with supplemental calories provided through medium-chain triglycerides (MCT).</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Acute rhabdomyolysis is treated with ample hydration and alkalization of the urine to protect renal function and to prevent acute renal failure secondary to myoglobinuria.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Fasting, myocardial irritation, dehydration, and high fat diet.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Timely evaluation of older and younger sibs of a proband to identify those who would benefit from institution of treatment and preventive measures.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>VLCAD deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="vlcad.Diagnosis">
        <title>Diagnosis</title>
        <sec id="vlcad.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Very long-chain acyl-CoA dehydrogenase (VLCAD) catalyzes the initial step of mitochondrial &#x003b2;-oxidation of long-chain fatty acids with a chain length of 14 to 20 carbons. VLCAD deficiency is associated with a range of phenotypes, including:</p>
          <list list-type="bullet">
            <list-item>
              <p>Severe early-onset cardiac and multi-organ failure form</p>
            </list-item>
            <list-item>
              <p>Hepatic or hypoketotic hypoglycemic form</p>
            </list-item>
            <list-item>
              <p>Later-onset episodic myopathic form</p>
            </list-item>
          </list>
        </sec>
        <sec id="vlcad.Testing">
          <title>Testing</title>
          <p><bold>Acylcarnitine analysis.</bold> Plasma or dried blood spot comprehensive acylcarnitine analysis using tandem mass spectrometry and measuring C4-C20 straight-chain acyl-carnitine esters, 3-hydroxy-acyl carnitine esters, and unsaturated acyl-carnitine esters is most sensitive when collected during a period of metabolic stress, such as fasting. The key metabolites that are most often abnormal in VLCAD deficiency are C14:1, C14:2, C14, and C12:1 [<xref ref-type="bibr" rid="vlcad.REF.mchugh.2011.230">McHugh et al 2011</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Although cut-off/abnormal values vary by age, method of collection, and laboratory, a C14:1 level greater than 1 mmol/L on an initial newborn screening test strongly suggests VLCAD deficiency. Individuals with this level or higher should be assumed to have VLCAD deficiency.</p>
            </list-item>
            <list-item>
              <p>Levels of C14:1 greater than 0.8 mmol/L suggest VLCAD deficiency but may also occur in carriers and some healthy individuals having no ACADVL pathogenic variants.</p>
            </list-item>
            <list-item>
              <p>Post-analytic tools, such as those developed by the Region 4 Stork (R4S/CLIR) collaborative, may contribute to refinement of newborn screening cutoffs and inform clinicians regarding the likelihood of a true positive diagnosis of VLCAD in individual newborns [<xref ref-type="bibr" rid="vlcad.REF.hall.2014.889">Hall et al 2014</xref>, <xref ref-type="bibr" rid="vlcad.REF.merritt.2014.484">Merritt et al 2014</xref>].</p>
            </list-item>
          </list>
          <p>Note: (1) Diagnostic abnormalities may no longer be present if an individual has been fed or has been treated with an IV glucose infusion or if the episode prompting concern has resolved. (2) Newborn screening data have affirmed that acylcarnitine analysis during periods of physiologic wellness often fails to identify affected individuals who have the milder phenotypes. (3) Depending on the &#x0201c;cut-off&#x0201d; limits used, initial acylcarnitine screening often detects heterozygotes.</p>
          <p><bold>Analysis of fatty acid &#x003b2;-oxidation in cultured fibroblasts.</bold> In vitro incubation of cultured fibroblasts with C13-palmitate or unlabeled palmitate and carnitine may provide indirect evidence of impaired &#x003b2;-oxidation. Individuals with severe VLCAD deficiency typically accumulate excess tetradecanoyl (C14) carnitine, whereas individuals with less severe phenotypes may shift accumulation toward dodecanoyl (C12) carnitine. This test is often called the &#x0201c;in vitro probe study.&#x0201d;</p>
          <p><bold>Analysis of VLCAD enzyme activity.</bold> Measurement VLCAD enzyme activity in leukocytes, cultured fibroblasts, liver, heart, skeletal muscle, or amniocytes by the electron transfer flavoprotein or ferricineum reduction assay can be used to confirm the diagnosis of VLCAD deficiency. Better specificity has been noted when the products are separated and quantitated by high-performance liquid chromatography or tandem mass spectrometry (MS/MS).</p>
          <p><bold>Immunoreactive VLCAD protein antigen expression</bold> (an &#x0201c;immunoblot&#x0201d;). This test uses polyclonal, specific antibodies to make a semi-quantitative assessment of expressed VLCAD antigen levels in protein extracts derived from cultured fibroblasts. Levels lower than 10% of control are consistent with VLCAD deficiency.</p>
          <sec id="vlcad.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">ACADVL</italic> is the only gene in which pathogenic variants are known to cause VLCAD deficiency.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="vlcad.T.summary_of_molecular_genetic_tes" position="anchor" orientation="portrait">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in VLCAD Deficiency</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">ACADVL</italic>
                    </td>
                    <td headers="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Two pathogenic variants in 47/55 and one pathogenic variant in 8/55 families with clinical disease&#x000a0;<sup>3,&#x000a0;4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_vlcad.T.summary_of_molecular_genetic_tes_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="vlcad.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="vlcad" object-id="vlcad.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="vlcad.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="vlcad.TF.1.2">
                  <label>2. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="vlcad.TF.1.3">
                  <label>3. </label>
                  <p>
                    <xref ref-type="bibr" rid="vlcad.REF.andresen.1999.479">Andresen et al [1999]</xref>
                  </p>
                </fn>
                <fn id="vlcad.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis of all 20 exons and exon/intron boundaries detects pathogenic variants in 85%-93% of persons with VLCAD deficiency.</p>
                </fn>
                <fn id="vlcad.TF.1.5">
                  <label>5. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Interpretation of test results.</bold> In vitro functional assays have been developed to characterize pathogenic variants and understand how they cause the clinical aspects of the disease (see <xref ref-type="sec" rid="vlcad.Molecular_Genetics">Molecular Genetics</xref>, <bold>Pathogenic allelic variants</bold>).</p>
          </sec>
        </sec>
        <sec id="vlcad.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Acylcarnitine profile on analysis of plasma or a dried blood spot. Molecular genetic analysis is probably indicated in all individuals with levels higher than 0.8 mmol/L [<xref ref-type="bibr" rid="vlcad.REF.liebig.2006.1065">Liebig et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">ACADVL</italic> molecular genetic testing (sequence analysis, followed by deletion/duplication analysis if only one pathogenic variant is identified, or if there is strong suspicion of VLCADD and no pathogenic variants are found on sequencing):</p>
              <list list-type="bullet">
                <list-item>
                  <p>If two deleterious <italic toggle="yes">ACADVL</italic> variants are found, a presumptive diagnosis of VLCAD deficiency is made.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>o If one <italic toggle="yes">ACADVL</italic> pathogenic variant is found, functional assessment of &#x003b2;-oxidation through the in vitro probe study or direct VLCAD enzyme activity assay using protein extracts from cultured fibroblasts or lymphocytes is recommended.</p>
          <p>Note: Skin biopsy for studies on cultured fibroblasts is often obtained while awaiting molecular studies if suspicion of VLCAD deficiency is high. Cultured fibroblasts can be assessed for in vitro &#x003b2;-oxidation and acylcarnitine profiling [<xref ref-type="bibr" rid="vlcad.REF.roe.2001.55">Roe et al 2001</xref>], direct assay of VLCAD enzyme activity, and immunoreactive VLCAD protein.</p>
          <p>o If no <italic toggle="yes">ACADVL</italic> pathogenic variants are found, VLCAD deficiency is highly unlikely and consideration should be given to other disorders of long-chain fatty acid oxidation (see <xref ref-type="sec" rid="vlcad.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <p><bold>Population-based newborn screening</bold> using MS/MS technology has identified numerous affected individuals [<xref ref-type="bibr" rid="vlcad.REF.boneh.2006.166">Boneh et al 2006</xref>, <xref ref-type="bibr" rid="vlcad.REF.merritt.2014.484">Merritt et al 2014</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>All abnormal results on newborn screening should be followed by a confirmatory acylcarnitine profile as well as molecular genetic testing [<xref ref-type="bibr" rid="vlcad.REF.boneh.2006.166">Boneh et al 2006</xref>, <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/ACT/C14.pdf">ACMG-ACT Sheet</ext-link></named-content>, <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/ACT/Algorithms/Visio-C14-1_DM.pdf">ACMG Algorithm</ext-link></named-content>].</p>
              <p>Note: A significant number of individuals with an abnormal newborn screen have one <italic toggle="yes">ACADVL</italic> pathogenic variant and are likely heterozygotes (i.e., carriers) detected because of the high sensitivity of the initial acylcarnitine screening assay.</p>
            </list-item>
            <list-item>
              <p>Skin biopsy and culture of skin fibroblasts for assessment of &#x003b2;-oxidation of palmitate, enzyme assay of VLCAD activity, and/or immunoquantification of VLCAD antigen are also recommended.</p>
            </list-item>
          </list>
          <p><bold>Postmortem testing.</bold> The following have been used to identify fatty acid oxidation (FAO) disorders postmortem:</p>
          <list list-type="bullet">
            <list-item>
              <p>Biochemical testing of liver or bile for acylcarnitine elevations and histochemical analysis for microvesicular steatosis</p>
            </list-item>
            <list-item>
              <p>Studies on a post-mortem skin biopsy</p>
            </list-item>
            <list-item>
              <p>Elevated concentrations of C8-C16 free fatty acids in plasma</p>
            </list-item>
            <list-item>
              <p>Plasma or dried blood spot acyl-carnitine analyses by MS/MS</p>
            </list-item>
          </list>
          <p>If these analyses are suspicious, retrospective molecular genetic and biochemical testing of newborn blood spots can often be performed to confirm a diagnosis.</p>
        </sec>
      </sec>
      <sec id="vlcad.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="vlcad.Clinical_Description">
          <title>Clinical Description</title>
          <p>Three clinical groups of VLCAD deficiency have been reported [<xref ref-type="bibr" rid="vlcad.REF.andresen.1999.479">Andresen et al 1999</xref>].</p>
          <p><bold>Severe early-onset cardiac and multi-organ failure VLCAD deficiency</bold> typically presents in the first months of life with hypertrophic or dilated cardiomyopathy, pericardial effusion, and arrhythmias, as well as hypotonia, hepatomegaly, and intermittent hypoglycemia.</p>
          <p>Cardiomyopathy and arrhythmias are often lethal. Ventricular tachycardia, ventricular fibrillation, and atrioventricular block have been reported [<xref ref-type="bibr" rid="vlcad.REF.bonnet.1999.2248">Bonnet et al 1999</xref>]. Although the morbidity resulting from cardiomyopathy may be severe, cardiac dysfunction is reversible with early intensive supportive care and diet modification; normal cognitive outcome has been reported in these individuals.</p>
          <p><bold>Hepatic or hypoketotic hypoglycemic VLCAD</bold>
<bold>deficiency</bold> typically presents during early childhood with hypoketotic hypoglycemia and hepatomegaly (similar to MCAD deficiency) but without cardiomyopathy. Individuals with hypoglycemia associated with a large quantity of ketones on urine dipstick testing are less likely to have impairment of the fatty acid oxidation spiral than those with small or undetectable quantity of ketones, but ketones may be present in either group.</p>
          <p><bold>Later-onset episodic myopathic</bold>
<bold>VLCAD</bold>
<bold>deficiency,</bold> probably the most common phenotype, presents with intermittent rhabdomyolysis, muscle cramps and/or pain, and/or exercise intolerance. Hypoglycemia typically is not present at the time of symptoms. Ascertainment in adulthood has been reported [<xref ref-type="bibr" rid="vlcad.REF.hoffman.2006.657">Hoffman et al 2006</xref>].</p>
          <p><bold>Pathophysiology.</bold> The FAO spiral is a series of four reactions occurring in the mitochondrial matrix. The first step is catalyzed by four highly homologous, straight-chain acyl-CoA dehydrogenases with differing, but overlapping, substrate specificities:</p>
          <list list-type="bullet">
            <list-item>
              <p>Short (SCAD that uses C4-C6 fatty acyl-CoAs)</p>
            </list-item>
            <list-item>
              <p>Medium (MCAD; C6-C10 fatty acyl-CoAs)</p>
            </list-item>
            <list-item>
              <p>Long (LCAD; C10-C14 fatty acyl-CoAs)</p>
            </list-item>
            <list-item>
              <p>Very long (VLCAD; C14-C20 fatty acyl-CoAs)</p>
            </list-item>
          </list>
          <p>SCAD, MCAD, and LCAD are homotetramers localized to the mitochondrial matrix; VLCAD is a homodimer associated with the inner mitochondrial membrane. These four homologs share about 40% amino acid identity or similarity within the catalytic domain; all use flavin adenine dinucleotide as the electron-accepting cofactor. Electrons are fed into the electron transport chain via ETF and ETF dehydrogenase.</p>
          <p>The use of fat to supply energy is important at critical points of physiologic adaptation. In utero, the fetus derives a constant supply of energy from glucose supplied continuously via the placenta. Following birth, maternal milk (of which ~60% of calories are fat) becomes the major nutrient, and therefore, fat becomes the major energy source, especially in the heart and other highly oxidative organs such as kidney and skeletal muscle [<xref ref-type="bibr" rid="vlcad.REF.hale.1985.666">Hale et al 1985</xref>, <xref ref-type="bibr" rid="vlcad.REF.aoyama.1993.1369">Aoyama et al 1993</xref>].</p>
          <p>The heart constantly uses fatty acids for energy. In contrast, the liver uses nutrients delivered directly during the absorptive phase of digestion and controls the short- and medium-term storage and distribution of energy from glycogenolysis and gluconeogenesis. However, during longer periods of fasting, the liver uses acetyl CoA to generate ketone bodies. The brain adapts to fasting by switching to a ketone economy, reducing the need for glucose as the energy source. With exercise, especially prolonged exercise, slow skeletal muscles use longer-chain FAO to generate energy. In summary, the adaptation to fasting depends on the supply of energy, the rate of consumption and preferred substrate, and physiologic backup mechanisms to provide alternative sources of energy in times of stress or transition.</p>
          <p>As one of the first enzymes in the FAO spiral, the enzyme VLCAD controls a critical point in the supply of electrons to the respiratory chain, and also provides a pathway permissive to the production of ketones. It would be expected that significant reduction at this step of fatty acid oxidation would impair the ability to transition successfully from fetal to neonatal life, to maintain cardiac output, to adapt to long fasting, and to generate energy for exercise. All of the above difficulties have been observed in VLCAD deficiency. The most severe defects result in early-infantile cardiomyopathy, hepatomegaly, hypotonia, and intermittent hypoglycemia.</p>
        </sec>
        <sec id="vlcad.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>As a general rule, a strong genotype-phenotype correlation exists in VLCAD deficiency [<xref ref-type="bibr" rid="vlcad.REF.andresen.1999.479">Andresen et al 1999</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Severe disease is associated with no residual enzyme activity, often resulting from null variants. Approximately 81% of pathogenic truncating variants in <italic toggle="yes">ACADVL</italic> are associated with the severe early onset form [<xref ref-type="bibr" rid="vlcad.REF.andresen.1999.479">Andresen et al 1999</xref>]</p>
            </list-item>
            <list-item>
              <p>Milder childhood and adult forms are often associated with residual enzyme activity, resulting from one or two pathogenic missense variants. The common <xref ref-type="table" rid="vlcad.T.selected_acadvl_allelic_variants">p.Val283Ala</xref> variant has usually been associated with the mild phenotypes [<xref ref-type="bibr" rid="vlcad.REF.spiekerkoetter.2009.498">Spiekerkoetter et al 2009</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="vlcad.Penetrance">
          <title>Penetrance</title>
          <p>Severe forms are suspected to be fully penetrant.</p>
          <p>Since the later-onset forms may have vague or intermittent symptoms, it is possible that some individuals will have no symptoms during their lifetime.</p>
        </sec>
        <sec id="vlcad.Nomenclature">
          <title>Nomenclature</title>
          <p>When the severe phenotype of VLCAD deficiency was described initially by <xref ref-type="bibr" rid="vlcad.REF.hale.1985.666">Hale et al [1985]</xref>, it was attributed to deficiency of the enzyme LCAD. The correct identification of the deficient enzyme, VLCAD, was made by <xref ref-type="bibr" rid="vlcad.REF.aoyama.1993.1369">Aoyama et al [1993]</xref>.</p>
        </sec>
        <sec id="vlcad.Prevalence">
          <title>Prevalence</title>
          <p>Complete ascertainment by newborn screening is not assured, but the incidence of VLCAD deficiency is now estimated at 1:30,000 in the US. Currently, more than 700 cases have been reported [<xref ref-type="bibr" rid="vlcad.REF.mchugh.2011.230">McHugh et al 2011</xref>] (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v13/n3/full/gim9201145a.html">full text</ext-link>).</p>
          <p>Newborn screening has demonstrated that VLCAD deficiency is more prevalent than previously suspected; however, the majority of children ascertained by newborn screening are asymptomatic during the few years of observation, suggesting that these individuals may have gone undiagnosed prior to the advent of population-based screening.</p>
        </sec>
      </sec>
      <sec id="vlcad.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with mutation of <italic toggle="yes">ACADVL</italic><bold>.</bold></p>
      </sec>
      <sec id="vlcad.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Infantile cardiomyopathy with evidence of abnormal fatty acid oxidation may be seen in the following disorders [<xref ref-type="bibr" rid="vlcad.REF.roe.2006.40">Roe et al 2006</xref>]:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="cdsp" document-type="chapter">Carnitine uptake disorder</related-object>
            </p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="cpt2" document-type="chapter">Severe carnitine palmitoyltransferase II (CPT II) deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) / trifunctional protein deficiency</p>
          </list-item>
          <list-item>
            <p>Carnitine-acylcarnitine translocase deficiency</p>
          </list-item>
          <list-item>
            <p>Severe forms of multiple acyl-CoA dehydrogenase deficiency</p>
          </list-item>
        </list>
        <p>The hepatic &#x0201c;hypoglycemic&#x0201d; form may be similar to <related-object link-type="booklink" source-id="gene" document-id="mcad" document-type="chapter">medium-chain acyl CoA dehydrogenase (MCAD) deficiency</related-object> or the electron transfer flavoprotein (ETF)/ETF ubiquinone (coenzyme Q) oxidoreductase defects which produce multiple acyl-CoA dehydrogenase deficiencies.</p>
        <p>Intermittent rhabdomyolysis is a feature of <related-object link-type="booklink" source-id="gene" document-id="gsd5" document-type="chapter">McArdle disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="cpt2" document-type="chapter">CPT II deficiency</related-object>, some primary myopathies, and trifunctional protein deficiency.</p>
        <p>A variety of cardiac, liver, brain, and muscle phenotypes were seen in the three published cases of ACAD9 deficiency, a newly described disorder involving oxidation of long-chain fatty acyl CoAs [<xref ref-type="bibr" rid="vlcad.REF.he.2007.87">He et al 2007</xref>]. However, more recent cases of ACAD9 deficiency more closely resemble a primary mitochondriopathy with Complex I deficiency [<xref ref-type="bibr" rid="vlcad.REF.haack.2010.1131">Haack et al 2010</xref>].</p>
      </sec>
      <sec id="vlcad.Management">
        <title>Management</title>
        <sec id="vlcad.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with VLCAD deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of baseline plasma (serum) creatine kinase (CK) concentration</p>
            </list-item>
            <list-item>
              <p>Measurement of baseline liver transaminases</p>
            </list-item>
            <list-item>
              <p>Cardiac echocardiography</p>
            </list-item>
            <list-item>
              <p>Electrocardiogram</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
          <p>Note: In the setting of acute disease, measurement of blood glucose concentration and blood ammonia concentration may be indicated.</p>
        </sec>
        <sec id="vlcad.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Frequently updated, succinct &#x0201c;emergency&#x0201d; care plans should detail the typical clinical issues (either those already experienced by the patient or those anticipated based on the diagnosis) and the importance of early management (e.g., use of IV glucose as an energy source, monitoring for cardiac rhythm disturbance, and monitoring of rhabdomyolysis), and avoidance of triggers (fasting, long-chain fats, and irritation of the myocardium) [<xref ref-type="bibr" rid="vlcad.REF.arnold.2009.81">Arnold et al 2009</xref>].</p>
          <p>Cardiac dysfunction is reversible with early, intensive supportive care (occasionally including extra-corporeal membrane oxygenation) and diet modification. See <xref ref-type="sec" rid="vlcad.Prevention_of_Primary_Manifestatio">Prevention of Primary Manifestations</xref>.</p>
        </sec>
        <sec id="vlcad.Prevention_of_Primary_Manifestatio">
          <title>Prevention of Primary Manifestations</title>
          <p>Individuals with the more severe forms are typically placed on a low-fat formula, with supplemental calories provided through medium-chain triglycerides (MCT). A variety of strategies for the low-fat diet are used, ranging from 13%-39% of calories as total fat, with an additional 15%-18% of calories supplied as MCT oil in those most strictly restricted for long-chain fats [<xref ref-type="bibr" rid="vlcad.REF.solis.2002.1800">Solis &#x00026; Singh 2002</xref>].</p>
          <p>Extra MCT has demonstrated benefit in older individuals with long-chain defects who have exercise intolerance. <xref ref-type="bibr" rid="vlcad.REF.gillingham.2006.58">Gillingham et al [2006]</xref> demonstrated improved exercise tolerance in individuals given 0.5 g/kg lean body weight 20 minutes prior to exercise. [<xref ref-type="bibr" rid="vlcad.REF.behrend.2012.110">Behrend et al 2012</xref>].</p>
          <p>Triheptanoin has been used in a few individuals with the goal of providing calories as well as providing anaplerotic carbons; however, the efficacy remains controversial. Formal clinical trials of triheptanoin are in progress (see <xref ref-type="sec" rid="vlcad.Therapies_Under_Investigation">Therapies Under Investigation</xref>).</p>
          <p>Severe exercise (e.g., military training) has unmasked symptoms in previously asymptomatic adults [<xref ref-type="bibr" rid="vlcad.REF.hoffman.2006.657">Hoffman et al 2006</xref>, <xref ref-type="bibr" rid="vlcad.REF.lafor_t.2009.324">Lafor&#x000ea;t et al 2009</xref>], emphasizing that exercise should be guided by the individual&#x02019;s tolerance level.</p>
          <p>The use of carnitine supplementation is controversial [<xref ref-type="bibr" rid="vlcad.REF.arnold.2009.81">Arnold et al 2009</xref>]: consensus as to whether additional carnitine is detrimental or efficacious has not been established.</p>
        </sec>
        <sec id="vlcad.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Acute rhabdomyolysis is treated with ample hydration and alkalization of the urine to protect renal function and to prevent acute renal failure secondary to myoglobinuria.</p>
        </sec>
        <sec id="vlcad.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Fasting, including periods of preparation and recovery from planned surgery or sedation [<xref ref-type="bibr" rid="vlcad.REF.vellekoop.2011.96">Vellekoop et al 2011</xref>]</p>
            </list-item>
            <list-item>
              <p>Myocardial irritation (e.g., cardiac catheterization)</p>
            </list-item>
            <list-item>
              <p>Dehydration (risk for acute tubular necrosis)</p>
            </list-item>
            <list-item>
              <p>High-fat diet (long-chain fats) including ketogenic or carbohydrate-restricted diets for the purpose of weight loss. Careful weight reduction has been accomplished by restricting long-chain fats and calories, supplementing with calories provided through medium-chain triglycerides (MCT), and limiting overnight catabolism with uncooked cornstarch [<xref ref-type="bibr" rid="vlcad.REF.zweers.2012.127">Zweers et al 2012</xref>]</p>
            </list-item>
            <list-item>
              <p>Volatile anesthetics and those that contain high doses of long-chain fatty acids such as propofol and etomidate [<xref ref-type="bibr" rid="vlcad.REF.vellekoop.2011.96">Vellekoop et al 2011</xref>]. However, the use of propofol for short duration procedures has been evaluated in individuals with LCHAD deficiency and not found to cause adverse events [<xref ref-type="bibr" rid="vlcad.REF.martin.2014.139">Martin et al 2014</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="vlcad.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk sibs.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variants in the family are not known, plasma or dried blood spot acylcarnitine analysis may not be sufficiently sensitive, and direct VLCAD assay of lymphocytes or FAO probe studies of cultured fibroblasts may be required.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="vlcad.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="vlcad.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>During pregnancy, placental and fetal &#x003b2;-oxidation may temporize or even improve maternal fatty acid &#x003b2;-oxidation [<xref ref-type="bibr" rid="vlcad.REF.mendezfigueroa.2010.558">Mendez-Figueroa et al 2010</xref>]. However, labor and post-partum periods are catabolic states and place the mother at higher risk for rhabdomyolysis and subsequent myoglobinuria. A management plan for labor and delivery has been proposed by <xref ref-type="bibr" rid="vlcad.REF.mendezfigueroa.2010.558">Mendez-Figueroa et al [2010]</xref>.</p>
        </sec>
        <sec id="vlcad.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Triheptanoin is a source of 7-carbon fatty acids which may be superior to medium-chain triglycerides, in that they provide a 3-carbon chain to promote anaplerosis [<xref ref-type="bibr" rid="vlcad.REF.roe.2002.259">Roe et al 2002</xref>].</p>
          <p>Bezafibrate, a PPAR pan agonist, has been shown to increase VLCAD enzyme activity in vitro in fibroblasts cultured from individuals with <italic toggle="yes">ACADVL</italic> pathogenic missense variants [<xref ref-type="bibr" rid="vlcad.REF.djouadi.2005.2695">Djouadi et al 2005</xref>, <xref ref-type="bibr" rid="vlcad.REF.gobinlimballe.2007.1133">Gobin-Limballe et al 2007</xref>]. It is not known whether this observation translates into reduction of clinical morbidity, and a small study published by <xref ref-type="bibr" rid="vlcad.REF.orngreen.2014.607">Orngreen et al [2014]</xref> suggests that exercise tolerance does not improve in response to oral bezafibrate.</p>
          <p>Dantrolene sodium, a muscle relaxant, may be useful as an adjunctive therapy in adult-onset rhabdomyolysis [<xref ref-type="bibr" rid="vlcad.REF.voermans.2005.844">Voermans et al 2005</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="vlcad.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="vlcad.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>VLCAD deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="vlcad.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">ACADVL</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>The genetic status of full sibs should be determined, since many individuals with VLCAD deficiency are not symptomatic during early childhood.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier of an <italic toggle="yes">ACADVL</italic> pathogenic variant is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with VLCAD deficiency are obligate heterozygotes (carriers) for an <italic toggle="yes">ACADVL</italic> pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of an <italic toggle="yes">ACADVL</italic> pathogenic variant.</p>
        </sec>
        <sec id="vlcad.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Molecular genetic testing.</bold> Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
          <p><bold>Biochemical genetic testing.</bold> Carrier status increases the likelihood of detection in a newborn screening program, as individuals with half of the normal VLCAD enzyme activity may have acylcarnitine levels near the upper limits of the normal range and the lower limits of the &#x0201c;possibly affected&#x0201d; range, particularly under the conditions of stress imposed by perinatal transition. However, testing of acylcarnitines, particularly in the unstressed individual, is not a reliable test for heterozygote status.</p>
          <p>Functional testing of fibroblasts, using the various protocols of palmitate oxidation and incorporation into small acylcarnitine species, also does not typically identify carriers.</p>
          <p>A direct VLCAD enzyme assay may provide better evidence of a carrier state than the options described above, but in most cases molecular genetic testing is preferred.</p>
        </sec>
        <sec id="vlcad.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="vlcad.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="vlcad.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">ACADVL</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options.</p>
          <p><bold>Biochemical genetic testing.</bold> Prenatal diagnosis of VLCAD deficiency based on the pattern of incorporation of labeled carbons (ranging from palmitate into shorter chain acylcarnitines) by cultured amniocytes that is similar to the fibroblast in vitro acylcarnitine profile has been described. Assay of VLCAD enzyme activity can distinguish between affected and unaffected cells. Absence of immunoreactive VLCAD on western blot analysis in those with severe VLCAD deficiency should provide additional information. As experience with these techniques is limited in the US, molecular genetic testing is preferred for prenatal testing.</p>
        </sec>
      </sec>
      <sec id="vlcad.Resources">
        <title>Resources</title>
      </sec>
      <sec id="vlcad.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="vlcad.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Very long-chain acyl-CoA dehydrogenase (VLCAD) catalyzes the initial step of mitochondrial &#x003b2;-oxidation of long-chain fatty acids with a chain length of 14 to 20 carbons.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">ACADVL</italic> comprises 20 exons spanning approximately 5.4 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="vlcad" object-id="vlcad.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> See <xref ref-type="table" rid="vlcad.T.selected_acadvl_allelic_variants">Table 2</xref>. Benign variants are few and primarily only tolerated outside of the conserved domain, which spans from approximately amino acid 70 through 480.</p>
          <p>In addition, an exonic sequence substitution, <xref ref-type="table" rid="vlcad.T.selected_acadvl_allelic_variants">p.Pro65Leu</xref>, results in an N-terminal in-frame splicing variant known as &#x02206;Ex3 VLCAD, which is missing 22 amino acids (residues 7-28 of the mature protein). In vitro studies have shown that the protein product of the &#x02206;Ex3 VLCAD splice variant is stable with very high specific activity and substrate profile comparable to the wild type VLCAD [<xref ref-type="bibr" rid="vlcad.REF.watanabe.2000.430">Watanabe et al 2000</xref>, <xref ref-type="bibr" rid="vlcad.REF.spiekerkoetter.2003.335">Spiekerkoetter et al 2003</xref>].</p>
          <p><bold>Pathogenic allelic variants.</bold> See <xref ref-type="table" rid="vlcad.T.selected_acadvl_allelic_variants">Table 2</xref>. Hundreds of pathogenic variants are known, including consensus splice site variants causing missplicing, short coding region duplications and deletions altering the reading frame, premature termination codon variants, and many missense variants that occur throughout the VLCAD protein.</p>
          <p>One of the most common pathogenic alleles, c.848T&#x0003e;C (p.Val283Ala), is observed in symptomatic compound heterozygotes and in homozygotes. It accounts for approximately 20% of all pathogenic alleles among individuals detected by newborn screening.</p>
          <p>The remaining pathogenic variants have often been reported as recurring, but their overall frequency is not well established.</p>
          <p>Racial and ethnic variants are reported; p.Thr409Met, for example, is observed more commonly among individuals of Pacific Island ancestry than in other populations.</p>
          <p>In vitro functional assays have been used in the research laboratory setting to characterize putative pathogenic missense variants and to investigate the clinical and biochemical aspects of VLCAD deficiency [<xref ref-type="bibr" rid="vlcad.REF.gobinlimballe.2007.1133">Gobin-Limballe et al 2007</xref>, <xref ref-type="bibr" rid="vlcad.REF.goetzman.2007.138">Goetzman et al 2007</xref>].</p>
          <table-wrap id="vlcad.T.selected_acadvl_allelic_variants" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">ACADVL</italic> Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant<break/>Classification</th>
                  <th id="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.49C&#x0003e;T</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu17Phe</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_4" rowspan="10" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000018.2">NM_000018.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000009.1">NP_000009.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.68G&#x0003e;A</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg23Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.128G&#x0003e;A</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly43Asp</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.194C&#x0003e;T</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro65Leu&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1038G&#x0003e;A</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala346Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_1" rowspan="5" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.848T&#x0003e;C</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val283Ala<break/>(Val243Ala)</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.779C&#x0003e;T</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr260Met<break/>(Thr220Met)</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1226C&#x0003e;T</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr409Met<break/>(Thr369Met)</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1322G&#x0003e;A</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly441Asp<break/>(Gly401Asp)</td>
                </tr>
                <tr>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1405C&#x0003e;T</td>
                  <td headers="hd_h_vlcad.T.selected_acadvl_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg469Trp<break/>(Arg429Trp)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="vlcad.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions. Note: Earlier references used protein nomenclature consistent with the mature protein and are provided in parentheses.</p>
              </fn>
              <fn id="vlcad.TF.2.2">
                <label>2. </label>
                <p>See <bold>Benign allelic variants</bold>.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The mature protein of 615 amino acids has a large, tightly conserved functional domain common to the acyl-CoA dehydrogenases. The major isoform encodes a precursor protein of 655 amino acids with a mitochondrial targeting sequence of 40 amino acids that is removed during uptake, resulting in the mature membrane-associated protein of 615 amino acid residues as reported by <xref ref-type="bibr" rid="vlcad.REF.aoyama.1995.273">Aoyama et al [1995]</xref> and <xref ref-type="bibr" rid="vlcad.REF.strauss.1995.10496">Strauss et al [1995]</xref>.</p>
          <p><bold>Abnormal gene product.</bold> The majority of abnormal (i.e., pathogenic) gene products result from missense variants, with reduced enzyme activity and/or reduced stability leading to lower steady state levels in mitochondria.</p>
        </sec>
      </sec>
      <sec id="vlcad.References">
        <title>References</title>
        <sec id="vlcad.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="vlcad.Literature_Cited.reflist0">
            <ref id="vlcad.REF.andresen.1999.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olpin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scholte</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ijlst</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pourfarzam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartlett</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>deKlerk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroeder</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corydon</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lund</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bross</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolund</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Am J Hum Genet</source>
                <volume>64</volume>
                <fpage>479</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">9973285</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.aoyama.1995.273">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Souri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ueno</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamijo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients.</article-title>
                <source>Am J Hum Genet</source>
                <volume>57</volume>
                <fpage>273</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">7668252</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.aoyama.1993.1369">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uchida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marble</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonsgard</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hashimoto</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase.</article-title>
                <source>Biochem Biophys Res Commun</source>
                <volume>191</volume>
                <fpage>1369</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">8466512</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.arnold.2009.81">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freedenberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garganta</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cederbaum</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boles</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <volume>96</volume>
                <fpage>81</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">19081279</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.behrend.2012.110">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Behrend</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoemaker</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sahn</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliot</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillingham</surname>
                    <given-names>MB</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation.</article-title>
                <source>Mol Genet Metab</source>
                <volume>105</volume>
                <fpage>110</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22030098</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.boneh.2006.166">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boneh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregersen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibrahim</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzanakos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaplito-Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis.</article-title>
                <source>Mol Genet Metab</source>
                <volume>88</volume>
                <fpage>166</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">16488171</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.bonnet.1999.2248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonnet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villain</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouvet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brivet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children.</article-title>
                <source>Circulation</source>
                <volume>100</volume>
                <fpage>2248</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">10577999</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.djouadi.2005.2695">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Djouadi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubrey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlemmer</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastin</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.</article-title>
                <source>Hum Mol Genet</source>
                <volume>14</volume>
                <fpage>2695</fpage>
                <lpage>703</lpage>
                <pub-id pub-id-type="pmid">16115821</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.gillingham.2006.58">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gillingham</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <volume>89</volume>
                <fpage>58</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">16876451</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.gobinlimballe.2007.1133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gobin-Limballe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Djouadi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olpin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukao</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAndrew</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastin</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy.</article-title>
                <source>Am J Hum Genet</source>
                <volume>81</volume>
                <fpage>1133</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">17999356</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.goetzman.2007.138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goetzman</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohsen</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ninness</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Expression and characterization of mutations in human very long-chain acyl-CoA dehydrogenase using a prokaryotic system.</article-title>
                <source>Mol Genet Metab</source>
                <volume>91</volume>
                <fpage>138</fpage>
                <lpage>47</lpage>
                <pub-id pub-id-type="pmid">17374501</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.haack.2010.1131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danhauser</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haberberger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoser</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strecker</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boehm</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uziel</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Invernizzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolinsky</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iuso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biskup</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mewes</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witting</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency.</article-title>
                <source>Nat Genet</source>
                <volume>42</volume>
                <fpage>1131</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21057504</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.hale.1985.666">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hale</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batshaw</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coates</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frerman</surname>
                    <given-names>FE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Long-chain acyl coenzyme A dehydrogenase deficiency: an inherited cause of nonketotic hypoglycemia.</article-title>
                <source>Pediatr Res</source>
                <volume>19</volume>
                <fpage>666</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">4022672</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.hall.2014.889">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McHugh</surname>
                    <given-names>DMS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Currier</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stoway</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Post-analytical tool improve performance of newborn screening by tandem mass spectrometry.</article-title>
                <source>Genet Med.</source>
                <volume>16</volume>
                <fpage>889</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">24875301</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.he.2007.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutledge</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murdoch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majumder</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pei</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency.</article-title>
                <source>Am J Hum Genet</source>
                <volume>81</volume>
                <fpage>87</fpage>
                <lpage>103</lpage>
                <pub-id pub-id-type="pmid">17564966</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.hoffman.2006.657">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paradise</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaplan</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl CoA dehydrogenase deficiency.</article-title>
                <source>Mil Med</source>
                <volume>171</volume>
                <fpage>657</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16895136</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.lafor_t.2009.324">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lafor&#x000ea;t</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acquaviva-Bourdain</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rigal</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brivet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penisson-Besnier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chabrol</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaigne</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boespflug-Tanguy</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laroche</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedat-Millet</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Behin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delevaux</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lomb&#x000e8;s</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andresen</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Diagnostic assessment and long-term follow-up of 13 patients with Very Long-Chain Acyl-Coenzyme A dehydrogenase (VLCAD) deficiency.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>19</volume>
                <fpage>324</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19327992</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.liebig.2006.1065">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liebig</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schymik</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spiekerkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels.</article-title>
                <source>Pediatrics</source>
                <volume>118</volume>
                <fpage>1065</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16950999</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.martin.2014.139">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillingham</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Use of propofol for short duration procedures in children with long chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiencies.</article-title>
                <source>Mol Genet Metab</source>
                <volume>112</volume>
                <fpage>139</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">24780638</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.mchugh.2011.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McHugh</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cameron</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdulrahman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adair</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Nuaimi</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>&#x000c5;hlman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonozzi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Archer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Au</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auray-Blais</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamforth</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beckmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pino</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berberich</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Binard</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boemer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonham</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breen</surname>
                    <given-names>NN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caggana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caldwell</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camilot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryant</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caggana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caldwell</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camilot</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carducci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cariappa</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlisle</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassanello</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castilla</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakraborty</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chandrasekar</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramos</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheillan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chien</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Childs</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chrastina</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sica</surname>
                    <given-names>YC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Juan</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colandre</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espinoza</surname>
                    <given-names>VC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corso</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Currier</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cyr</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Czuczy</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Apolito</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sain-Van der Velden</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delgado Pecellin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Gangi</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Stefano</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dotsikas</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Downing</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Downs</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dymerski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rueda</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elvers</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eaton</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckerd</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>El Mougy</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eroh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Espada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fawbush</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fijolek</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franzson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazier</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bermejo</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gavrilov</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerace</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giordano</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irazabal</surname>
                    <given-names>YG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greed</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grier</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grycki</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gulamali-Majid</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagar</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannon</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haslip</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hassan</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hietala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Himstedt</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoggatt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkins</surname>
                    <given-names>PV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hougaard</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwu</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hynes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ibarra-Gonz&#x000e1;lez</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingham</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ivanova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacox</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>John</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>J&#x000f3;nsson</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karg</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopper</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katakouzinos</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khneisser</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knoll</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koneski</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kozich</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kouapei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohlmueller</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremensky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>la Marca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavochkin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehotay</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lepage</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd-Puryear</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loukas</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luedtke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maffitt</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magee</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manning</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marie</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadachi</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayfield Gibson</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayne</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCallister</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClure</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGill</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKeever</surname>
                    <given-names>CD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McNeilly</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrissey</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moutsatsou</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulcahy</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikoloudis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norgaard-Pedersen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oglesbee</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oltarzewski</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ombrone</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ojodu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papakonstantinou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reoyo</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pass</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettersen</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitt</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porter</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poston</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Price</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Queijo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quesada</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Randell</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ranieri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddic</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reuben</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricciardi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rocha</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roche</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mellado</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juan-Fita</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruoppolo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutledge</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sahai</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Blanco</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santiago-Borrero</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schenone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schoos</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schweitzer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seashore</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seeterlin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sesser</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sevier</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shone</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skrinska</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanley</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strovel</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunny</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takats</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanyalcin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teofoli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomashitis</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Domingos</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tortorelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tzanakos</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valiente</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vela-Amieva</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilarinho</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von D&#x000f6;beln</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorster</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiss</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcken</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiley</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woontner</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wright</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yahyaoui</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yssel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zakowicz</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project.</article-title>
                <source>Genet Med.</source>
                <volume>13</volume>
                <fpage>230</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">21325949</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.mendezfigueroa.2010.558">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mendez-Figueroa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shchelochkov</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaibani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aagaard-Tillery</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shinawi</surname>
                    <given-names>MS</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical and biochemical improvement of very long-chain acyl-CoA dehydrogenase deficiency in pregnancy.</article-title>
                <source>J Perinatol</source>
                <volume>30</volume>
                <fpage>558</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">20668464</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.merritt.2014.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Merritt</surname>
                    <given-names>JL</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Vedal</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Au</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feuchtbaum</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermerath</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sesser</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Infants suspected to have very-log chain acyl-CoA dehydrogenase deficiency from newborn screening.</article-title>
                <source>Mol Genet Metab</source>
                <volume>111</volume>
                <fpage>484</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">24503138</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.orngreen.2014.607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orngreen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madsen</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Presisler</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vissing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laforet</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.</article-title>
                <source>Neurology</source>
                <volume>82</volume>
                <fpage>607</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">24453079</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.roe.2002.259">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunengraber</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride.</article-title>
                <source>J Clin Invest</source>
                <volume>110</volume>
                <fpage>259</fpage>
                <lpage>69</lpage>
                <pub-id pub-id-type="pmid">12122118</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.roe.2001.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharma</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabot</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Oxidation of unsaturated fatty acids by human fibroblasts with very-long-chain acyl-CoA dehydrogenase deficiency: aspects of substrate specificity and correlation with clinical phenotype.</article-title>
                <source>Clin Chim Acta</source>
                <volume>312</volume>
                <fpage>55</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">11580910</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.roe.2006.40">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>BZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianey-Saban</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweetman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts.</article-title>
                <source>Mol Genet Metab</source>
                <volume>87</volume>
                <fpage>40</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16297647</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.solis.2002.1800">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Solis</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Management of fatty acid oxidation disorders: a survey of current treatment strategies.</article-title>
                <source>J Am Diet Assoc</source>
                <volume>102</volume>
                <fpage>1800</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">12487544</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.spiekerkoetter.2009.498">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spiekerkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grotzke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baumgartner</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boehles</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Das</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haase</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennemann</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karall</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Klerk</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knerr</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roschinger</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwab</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheible</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayatepek</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>32</volume>
                <fpage>498</fpage>
                <lpage>505</lpage>
                <pub-id pub-id-type="pmid">19452263</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.spiekerkoetter.2003.335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spiekerkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zytkovicz</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>J Pediatr.</source>
                <volume>143</volume>
                <fpage>335</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">14517516</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.strauss.1995.10496">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Powell</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hale</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahuja</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brackett</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>HF</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood.</article-title>
                <source>Proc Natl Acad Sci USA.</source>
                <volume>92</volume>
                <fpage>10496</fpage>
                <lpage>500</lpage>
                <pub-id pub-id-type="pmid">7479827</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.vellekoop.2011.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vellekoop</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diekman</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Tuijl</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>MMC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Hasselt</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Perioperative measures in very long chain acyl-CoA dehydrogenase deficiency.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>103</volume>
                <fpage>96</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21333574</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.voermans.2005.844">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Voermans</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poels</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluijtmans</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The effect of dantrolene sodium in Very Long Chain Acyl-CoA Dehydrogenase Deficiency.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>15</volume>
                <fpage>844</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16288870</pub-id>
              </element-citation>
            </ref>
            <ref id="vlcad.REF.watanabe.2000.430">
              <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Watanabe</surname><given-names>H</given-names></name><name name-style="western"><surname>Orii</surname><given-names>KE</given-names></name><name name-style="western"><surname>Fukao</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>XQ</given-names></name><name name-style="western"><surname>Aoyama</surname><given-names>T</given-names></name></person-group>IJIst L, Ruiter J, Wanders RJ, Kondo N<year>2000</year><article-title>Molecular basis of very long chain acyl-CoA dehydrogenase deficiency in three Israeli patients: identification of a complex mutant allele P65L and K247Q mutations, the former being an exonic mutation causing exon 3 skipping.</article-title><source>Hum Mutat.</source><volume>15</volume><fpage>430</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10790204</pub-id></mixed-citation>
            </ref>
            <ref id="vlcad.REF.zweers.2012.127">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zweers</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>den Heijer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Valk</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Successful weight loss in two adult patients diagnosed with late-onset long-chain Fatty Aid oxidation defect.</article-title>
                <source>J Inher Met Disease Rep.</source>
                <volume>6</volume>
                <fpage>127</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23430950</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="vlcad.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="vlcad.Suggested_Reading.reflist0">
            <ref id="vlcad.REF.schuler.2005.7">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schuler</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gower</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>PA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Synergistic heterozygosity in mice with inherited enzyme deficiencies of mitochondrial fatty acid beta-oxidation.</article-title>
                <source>Mol Genet Metab</source>
                <volume>85</volume>
                <fpage>7</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">15862275</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="vlcad.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="vlcad.Author_History">
          <title>Author History</title>
          <p>Jessica A Connor, MS (2014-present)Nancy D Leslie, MD (2009-present)Kerry Shooner, MS, CGC; Cincinnati Children&#x02019;s Hospital Medical Center (2009-2014)Arnold W Strauss, MD (2009-present)Brad T Tinkle, MD, PhD; Cincinnati Children&#x02019;s Hospital Medical Center (2009-2014)C Alexander Valencia, PhD (2014-present)Kejian Zhang, MD, MBA (2009-present)</p>
        </sec>
        <sec id="vlcad.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>11 September 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 September 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>28 May 2009 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>29 December 2008 (ks) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
